Vertex to Buy Crinetics for $10B, Adding Acromegaly Drug

Vertex Pharmaceuticals (VRTX) will acquire Crinetics Pharmaceuticals (CRNX) for roughly $10 billion in cash, the two companies said Wednesday. The net purchase price comes to about $8.8 billion after subtracting the cash Crinetics holds.

Crinetics' lead asset is Paltusotine, a once-daily oral drug for acromegaly that the companies expect to launch later this year pending regulatory approval. The drug targets a condition that currently relies on injectable therapies. Crinetics also has a pipeline candidate for carcinoid syndrome, a rare neuroendocrine tumor complication, in late-stage trials.

Vertex said the acquisition adds a commercial-stage endocrinology franchise and a set of preclinical programs that could expand the company's reach beyond cystic fibrosis. The deal is expected to close in the second quarter of 2025, subject to regulatory approvals and a Crinetics shareholder vote.

Vertex plans to fund the acquisition through cash on hand and new debt. The company had about $12 billion in cash and marketable securities as of the end of 2024, according to its latest quarterly filing.

The deal represents a premium of roughly 75% to Crinetics' closing price on Tuesday. Crinetics shares rose 72% in premarket trading on the announcement. Vertex shares slipped about 1%.

Wall Street analysts have been speculating about Vertex's next major move for months. The company's cystic fibrosis franchise, built on Trikafta and related drugs, generates over $10 billion in annual revenue. That franchise faces a patent cliff in the early 2030s. Vertex has been investing in pain and sickle cell disease. None of those programs have reached the market yet. Paltusotine gives Vertex a near-term revenue stream outside CF. Analysts project peak sales of $1 billion to $2 billion for the acromegaly drug.

The acquisition also brings Crinetics' research platform, which includes expertise in oral peptide and small molecule development for endocrine diseases. That infrastructure could support Vertex's broader pipeline ambitions.

Vertex's Alpha Score sits at 63 out of 100, a Moderate rating from AlphaScala's proprietary model. The score reflects the company's strong cash flows and dominant CF position balanced against pipeline risk and patent exposure. The acquisition of Crinetics adds a new pillar. It does not eliminate the longer-term overhang from CF patent expirations.

A shareholder vote is expected within 60 days. The companies set a termination fee of $300 million payable by Crinetics under certain conditions. The VRTX stock page provides ongoing updates on the deal timeline and Vertex's post-acquisition financials.